Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) said its management team will participate in investor conferences in March 2026. Presentations are scheduled at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026 at 10:30–11:00 AM ET and a Barclays 28th Annual Global Healthcare fireside chat at 1:00–1:25 PM ET. Both sessions will be available via webcast.
Humacyte (Nasdaq: HUMA) presented 36-month V005 trial results for Symvess at the VESS Annual Winter Meeting on Feb 18, 2026. Symvess showed 92.9% infection-free rate from months 3–36, 87.3% limb salvage at 12 months and durable vessel diameter with no dilatation or narrowing through 36 months.
No conduit-related deaths or spontaneous structural failures were reported; three conduit infections occurred overall.
Humacyte (Nasdaq: HUMA) said the FY2026 U.S. Department of Defense appropriations include targeted funding to support procurement and evaluation of biologic vascular repair technologies for traumatic extremity arterial injuries when autologous vein grafting is not feasible.
Symvess is described as the only human-derived bioengineered blood vessel approved by the FDA; the release highlights a retrospective battlefield study of 16 patients with 100% survival, zero amputations, and zero conduit infections. Safety risks, including graft rupture, anastomotic failure, and thrombosis, are noted with boxed warning language and recommended antiplatelet therapy.
Humacyte (Nasdaq: HUMA) released a five-year retrospective analysis of hospital charges and payer costs for extremity arterial injury (2018–2023). The average initial hospital charge was $316,600 per patient; graft infection and amputation raised charges by about $589,921 and $492,986, respectively, while average reimbursed costs were far lower ($84,598 for infection, $116,611 for amputation). 26% of repairs used conduits other than autologous vein. Humacyte highlights Symvess as an off-the-shelf biologic conduit with markedly lower infection and amputation rates versus historical controls and reports positive three-year V005 Phase 2/3 results supporting limb salvage benefits.
Humacyte (Nasdaq: HUMA) plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for Symvess (acellular tissue engineered vessel) for arterial trauma repair in Q1 2026. The company expects a 120 working-day review period, citing existing FDA approval of Symvess. Humacyte is coordinating with Israeli surgeons who participated in the V005 Phase 2/3 trial and who have requested product access.
Humacyte said recently published positive three-year V005 results provide the first prospective long-term data for traumatic arterial repair using an off-the-shelf biologic conduit; Symvess is designed for immediate availability and has shown low infection rates and high limb-salvage rates in trauma settings.
Humacyte (Nasdaq: HUMA) announced publication (Dec 22, 2025) of long-term results for Symvess in the Journal of Vascular Surgery Cases, Innovations and Techniques.
The prospective V005 Phase 2/3 study followed 54 extremity arterial trauma patients up to 36 months. Key findings: infection-free rate 92.9% from months 3–36, limb salvage 87.3% at 12 months and 82.5% at 24 months, only three conduit infections, and no spontaneous ruptures or unprovoked structural failures attributed to Symvess.
The device is indicated when urgent revascularization is needed and autologous vein graft is not feasible; prescribing information includes a boxed warning on graft failure and recommendations for antiplatelet therapy.
Humacyte (Nasdaq: HUMA) announced a credit facility up to $77.5 million with Avenue Venture Opportunities Fund II, L.P., including a four-year term and an initial tranche of $40 million fully funded at close.
Proceeds from the initial tranche were used primarily to retire existing debt. An additional $37.5 million of tranches are available subject to revenue, regulatory approvals, liquidity conditions and lender approval for the third tranche. Management cited plans for expanded Symvess use, interim V012 Phase 3 dialysis results, and a first human coronary tissue engineered vessel study in 2026.
Humacyte (Nasdaq: HUMA) presented five podium talks at the 52nd VEITHsymposium on Nov 20, 2025, reporting clinical results for its acellular tissue engineered vessel (ATEV).
Key findings: histology up to 200 weeks post-implant showed progressive host recellularization into multi-layered vascular tissue; four DRIL cases for dialysis steal showed durable patency and safety with follow-up to 35.9 months; 17 wartime extremity trauma patients had continued high patency, 100% limb salvage, and zero conduit infections through two years; a randomized female subgroup showed superior 24-month patency versus autologous fistula; case reports showed feasibility in torso arterial trauma. For uses beyond the FDA-approved extremity vascular trauma indication, ATEV remains investigational.
Humacyte (Nasdaq: HUMA) announced six presentations on its Acellular Tissue Engineered Vessel (ATEV™) at the 52nd Annual VEITHsymposium in New York, November 18-22, 2025. The sessions detail clinical use and histologic evaluation of ATEV across vascular indications, including trauma, dialysis access, distal revascularization, and randomized trial outcomes.
Presentations scheduled for November 19 and 20, 2025, include two-year outcome data versus autologous vein grafts and fistulas, case reports from the CLN-PRO-V005 trial, female-specific two-year randomized trial outcomes, long-term histologic regeneration data, and a review of published outcomes across multiple vascular indications.
Humacyte (Nasdaq: HUMA) reported third-quarter 2025 results and a business update on November 12, 2025. Q3 revenue was $0.753M (including $0.703M from Symvess sales) and nine-month revenue was $1.571M. The company reported Q3 net loss of $17.5M and $19.8M cash at September 30, 2025, with ~$56.5M of net proceeds raised after quarter-end. Symvess commercial launch showed a sales ramp (from $0.1M in Q2 to $0.703M in Q3) with 25 VAC approvals covering 92 hospitals and 16 hospitals ordered product. Clinical and regulatory progress includes positive V007 two-year dialysis data, 109 patients enrolled in V012, planned supplemental BLA submission in H2 2026, and an IND submitted for a CABG first-in-human study in 2026. A new U.S. patent for a bioengineered esophagus was granted, extending IP protection into 2041.